The vaccinia virus E3L gene product interacts with both the regulatory and the substrate binding regions of PKR: Implications for PKR autoregulation

Virology

Volumn 250, Issue 2, 1998, Pages 302-315

  Sharp, T V ^a   Moonan, F ^a   Romashko, A ^a   Joshi, B ^a   Barber, G N ^b   Jagus, R ^a,c  

^a UNIVERSITY OF MARYLAND BIOTECHNOLOGY INSTITUTE   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MARYLAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA GALACTOSIDASE; DOUBLE STRANDED RNA; GENE PRODUCT; GLUTATHIONE; HYBRID PROTEIN; INTERFERON; PROTEIN KINASE; PROTEIN SERINE THREONINE KINASE; RECOMBINANT PROTEIN; RNA BINDING PROTEIN; SULFUR 35;

ANTIVIRAL ACTIVITY; ARTICLE; AUTOPHOSPHORYLATION; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; ENZYME SUBSTRATE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN SYNTHESIS INHIBITION; RNA BINDING; SACCHAROMYCES CEREVISIAE; VACCINIA VIRUS;

ANIMALIA; DNA VIRUSES; SACCHAROMYCES CEREVISIAE; VACCINIA; VACCINIA VIRUS;

EID: 0032566917     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1006/viro.1998.9365     Document Type: Article

References (88)

1. Akkaraju G. R., Whitaker-Dowling P., Youngner J. S., Jagus R. Vaccinia virus SKIF prevents translational inhibition by dsRNA in reticulocyte lysate. J. Biol. Chem. 264:1989;10321-10325.
2. Barber G. N., Jagus R., Meurs E. F., Hovanessian A., Katze M. G. Molecular mechanisms responsible for malignant transformation by regulatory and catalytic domain variants of PKR. J. Biol. Chem. 270:1995;17423-17428.
3. Barber G. N., Tomita T., Hovanessian A. G., Meurs E., Katze M. G. Functional expression and characterization of interferon-induced double-stranded RNA activated P68 protein kinase fromEscherichia coli. Biochemistry. 30:1991;10356-10361.
4. Beattie E., Denzler K. L., Tartaglia J., Perkus M. E., Paoletti E., Jacobs B. L. Reversal of the interferon-sensitive phenotype of vaccinia virus lacking E3L by expression of the reovirus S4 gene. J. Virol. 69:1995a;499-505.
5. Beattie E., Tartaglia J., Paoleti E. Distinct patterns of interferon sensitivity in cells infected with vaccinia virus K3L and E3L deletion mutants. Virology. 210:1995b;254-263.
6. Beattie E., Tattaglia J., Paoletti E. Vaccinia virus eIF-2α homologue abrogates the antiviral effects of interferon. Virology. 183:1991;419-422.
7. Benkirane M., Neuveut C., Chun R. F., Smith S. M., Samuel C. E., Gatignol A., Jeang K. T. Oncogenic potential of Tar RNA binding protein TRBP and its regulatory interaction with PKR. EMBO J. 16:1997;611-624.
8. Black T. L., Safer B., Hovanessian A. G., Katze M. G. Cellular PKR is highly phosphorylated and activated yet significantly degraded during poliovirus infection. J. Virol. 63:1989;2244-2251.
9. Bycroft M., Grunert S., Murzin A. G., Proctor M., St. Johnston D. NMR solution structure of a dsRNA binding domain from Drosophilastaufen. EMBO J. 14:1995;3572-3584.
10. Carpick B. W., Graziano V., Schneider D., Maitra R. K., Williams B. R. G. Characterization of the solution complex between the interferon-induced, dsRNA-activated protein kinase and HIV-I trans-activating region RNA. J. Biol. Chem. 272:1997;9510-9516.
11. Carroll K., Elroy-Stein O., Moss B., Jagus R. Recombinant vaccinia virus K3L gene product prevents activation of double-stranded RNA-dependent initiation factor 2 alpha-specific proten kinase. J. Biol. Chem. 268:1993;12837-12842.
12. Chang H.-W., Jacobs B. L. Identification of a conserved motif that is necessary for binding of the vaccinia virus E3L gene product to dsRNA. Virology. 194:1993;537-547.
13. Chang H.-W., Uribe L. H., Jacobs B. L. Rescue of vaccinia virus lacking the E3L gene by mutants of E3L. J. Virol. 69:1995;6605-6608.
14. Chang H.-W., Watson J. L., Jacobs B. L. The E3L gene of vaccinia virus encodes an inhibitor of PKR. Proc. Natl. Acad. Sci. 89:1992;4825-4829.
15. Clemens M. J. Protein kinases that phosphorylate eIF2 and eIF2B, and their role in eukaryotic cell translational control. Translational Control. 1996;Cold Spring Harbor Laboratory Press, Cold Spring Harbor. p. 139-172.
16. Clemens M. J., Elia A. The double-stranded RNA-dependent protein kinase PKR: Structure and function. J. Interferon Cytokine Res. 17:1997;503-524.
17. Cosentino G. P., Venkatesan S., Serluca F. C., Green S. R., Mathews M. B., Sonenberg N. The dsRNA-dependent protein kinase, PKR, and TAR binding protein, TRBP, form homo- and heterodimersin vivo. Proc. Natl. Acad. Sci. USA. 92:1995;9445-9449.
18. Craig A. W. B., Cosentino G. P., Donze O., Sonenberg N. The kinase insert domain of interferon-induced protein kinase, PKR, is required for activity but not for interaction with the pseudosubstrate K3L. J. Biol. Chem. 271:1996;24526-24533.
19. Davies M. V., Chang H.-W., Jacobs B. L., Kaufman R. J. The E3L and K3L vaccinia virus gene products stimulate translation through inhibition of PKR by different mechanisms. J. Virol. 67:1993;1688-1692.
20. Davies M. V., Elroy-Stein O., Jagus R., Moss B., Kaufman R. J. Vaccinia virus K3L gene product potentiates translation by inhibiting double-stranded RNA-activated protein kinase and phosphorylation of the alpha subunit of eukaryotic initiation factor 2. J. Virol. 66:1992;1943-1950.
21. DeHaro C. The eIF2α kinases and the control of protein synthesis. FASEB J. 10:1996;1378-1387.
22. Dever T. E., Sripriya R., McLachlin J. R., Lu J., Fabian J. R., Kimball S. R., Miller L. K. Disruption of cellular translational control by a viral truncated eukaryotic translation initiation factor 2 alpha kinase homolog. Proc. Natl. Acad. Sci. USA. 95:1998;4164-4169.
23. Feng G.-S., Chong K., Kumar A., Williams B. R. G. Identification of dsRNA binding domains in interferon-induced eIF-2α-PK. Proc. Natl. Acad. Sci. USA. 89:1992;5447-5451.
24. Fields S., Song O. A novel genetic system to detect protein-protein interactions. Nature. 340:1989;245-246.
25. Galabru J., Hovanessian A. R. Autophosphorylation of dsRNA-dependent protein kinase. J. Biol. Chem. 262:1987;15538-15544.
26. Gale M., Tan S. L., Wambach M., Katze M. G. Interaction of the interferon-induced kinase, PKR, with inhibitory proteins p58 and vaccinia virus K3L is mediated by unique domains - implications for kinase function. Mol. Cel. Biol. 16:1996;4172-4181.
27. George C. X., Thomis D. C., Mccormack S. J., Svahn C. M., Samuel C. E. Characterization of the heparin-mediated activation of PKR. Virology. 221:1996;180-188.
28. Gietz D., St. Jean A., Woods R. A., Schiestl R. H. Improved method for high efficiency transformation of intact yeast cells. Nucleic Acids Res. 20:1992;1425.
29. Goebel S. J., Johnson G. P., Perkus M. E., Davis S. W., Winslow J. P., Paoletti E. The complete sequence of vaccinia virus. Virology. 179:1990;247-266.
30. Green S. R., Mathews M. B. Two RNA binding motifs in the dsRNA-activated protein kinase, DAI. Genes Dev. 6:1992;2478-2490.
31. Haig D. M., McInnes C. J., Thomson J., Wood A., Bunyan K., Mercer A. The orf virus OV20.0L gene product is involved in interferon resistance and inhibits an interferon-inducible, double-stranded RNA-dependent kinase. Immunology. 93:1998;335-340.
32. Ho C. K., Shuman S. Mutational analysis of the vaccinia virus E3 protein defines amino acid residues involved in E3 binding to dsRNA. J. Virol. 70:1996a;2611-2614.
33. Ho C. K., Shuman S. Physical and functional characterization of the dsRNA binding protein encoded by vaccinia virus. Virology. 217:1996b;272-284.
34. House C., Kemp B. E. Protein kinase C contains a pseudosubstrate prototope in its regulatory domain. Science. 238:1987;1726-1728.
35. Ito T., Jagus R., May S. IL-3 stimulates protein synthesis by regulating dsRNA-dependent protein kinase (PKR). Proc. Natl. Acad. Sci. USA. 91:1994;7455-7459.
36. Iwabuchis K., Li B., Bartel P., Fields S. Use of the two-hybrid system to identify the domain of p53 involved in oligomerization. Oncogene. 8:1993;1693-1696.
37. Jacobs B. L., Langland J. O. When two strands are better than one: The mediators and modulators of the cellular responses to double-stranded RNA. Virology. 219:1996;339-349.
38. Jagus R. Characterization of in vitro translation products. Methods Enzymol. 152:1987;296-306.
39. Jagus R., Gray M. E. Proteins that interact with PKR. Biochimie (Paris). 76:1994;77-9-791.
40. Johnson G. A., Gautsch J. W., Sportsman J. R., Elder J. H. Improved technique utilizing dried milk for analysis of proteins and nucleic acids transferred to nitrocellulose. Gene Anal. Tech. 1:1984;3-8.
41. Katze M. G. Games viruses play: A strategic initiative against PKR. Semin. Virol. 4:1993;259-268.
42. Katze M. G. Regulation of the interferon-induced PKR: Can viruses cope. Trends Microbiol. 3:1995;75-78.
43. Katze M. G., Wambach M., Wong M.-L., Garfinkel M., Meurs E., Williams B., Hovanessian A. G., Barber G. N. Functional expression and RNA binding analysis of dsRNA dependent PKR in a cell-free system. Mol. Cel. Biol. 11:1991;5497-5505.
44. Kawagishi-Kobayashi M., Silverman J. B., Ung T. L., Dever T. E. Regulation of the protein kinase PKR by the vaccinia pseudosubstrate inhibitor K3L is dependent on residues conserved between K3L and the PKR substrate eIF2α Mol. Cel. Biol. 17:1997;4146-4158.
45. Kemp B. E., Pearson R. B. Intrasteric regulation of protein kinases and phosphatases. Biochim. Biophys. Acta. 1094:1991;67-76.
46. Kharrat A., Macias M. J., Gibson T. J., Nilges M., Pastore A. Structure of the dsRNA binding domain ofE. coli. EMBO J. 14:1995;3572-3584.
47. Kim U., Wang Y., Sanford T., Zeng Y., Nishikura K. Molecular cloning of cDNA for dsRNA-adenosine deaminase: A candidate enzyme for RNA processing. Proc. Natl. Acad. Sci. USA. 91:1994;11457-11461.
48. Langland J. O., Pettiford S., Jiang B., Jacobs B. L. Products of the porcine group C rotavirus NSP3 gene bind specifically to double-stranded RNA and inhibit activation of the interferon-induced protein kinase PKR. J. Virol. 68:1994;3821-3829.
49. Laurent A. G., Krust B., Galabru J., Svab J., Hovanessian A. G. Monoclonal antibodies to an interferon-induced Mr 68000 protein and their use for the detection of double-stranded RNA-dependent protein kinase in human cells. Proc. Natl. Acad. Sci. USA. 82:1985;4341-4345.
50. Lee T. G., Katze M. G. Cellular inhibitors of PKR. Prog. Mol. Subcell. Biol. 14:1993;48-65.
51. Lee T. G., Tang N., Thompson S., Miller J., Katze M. G. The 58-kDa cellular inhibitor of PKR is a member of the TPR family of proteins. Mol. Cel. Biol. 14:1994;2331-2342.
52. Mathews M. B. Viral evasion of cellular defense mechanisms: Regulation of DAI by RNA effectors. Semin. Virol. 4:1993;247-257.
53. Mathews M. B. Interactions between viruses and the cellular machinery for protein synthesis. Hershey J. W. B., Mathews M. B., Sonenberg N. Translational Control. 1996;505-548 Cold Spring Harbor Laboratory Press, Cold Spring Harbor.
54. McCormack S. J., Ortega L. G., Doohan J. P., Samuel C. E. Motif 1 of PKR is sufficient to mediate RNA binding activity. Virology. 198:1994;92-99.
55. McCormack S. J., Thomis D. C., Samuel C. E. Mechanism of interferon action: Identification of RNA binding domain within N-terminal region of the human RNA-dependent P1/eIF2 alpha kinase, PKR. Virology. 188:1992;47-56.
56. McMillan N. A., Carpick B. W., Hollis B., Toone W. M., Zamanian-Daryoush M., Williams B. R. Mutational analysis of the double-stranded RNA (dsRNA) binding domain of the dsRNA-activated protein kinase, PKR. J. Biol. Chem. 270:1995;2601-2606.
57. Meurs E., Chong K., Galabru J., Thoma N., M. K. I., Williams B. R. G., Hovanessian A. G. Molecular cloning and characterization of the double-stranded, RNA-activated protein kinase induced by interferon. Cell. 62:1990;379-390.
58. Meurs E., Watanabe Y., Kadereit S., Barber G. N., Katze M. G., Chong K., Williams B. R. G. Constitutive expression of human PKR in murine cells mediates phosphorylation of eIF-2α and partial resistance to EMC virus growth. J. Virol. 66:1992;5805-5814.
59. Moss B., Elroy-Stein O., Mizukami W. A., Fuerst T. R. New mammalian expression vectors. Nature. 348:1990;91-92.
60. O'Connell M. A., Krause S., Higuchi M., Hsuan J. J., Totty N., Jenny F. T., Keller W. Cloning of cDNAs encoding mammalian dsRNA-specific adenosine deaminase. Mol. Cell. Biol. 15:1995;1389-1397.
61. Ortega L. G., McCotter M. D., Henry G. L., McCormack S. J., Thomis D. C., Samuel C. E. Biochemical and genetic evidence for the intermolecular association of PKR from human cells. Virology. 215:1996;31-39.
62. Park H., Davies M. V., Langland J. O., Chang H. W., Nam Y. S., Tartaglia J., Paoletti E., Jacobs B. L., Kaufman R. J., Venkatesan S. TAR RNA-binding protein is an inhibitor of the interferon-induced protein kinase PKR. Proc. Natl. Acad. Sci. USA. 24:1994;4713-4717.
63. Patel R. C., Sen G. C. Identification of dsRNA binding domain of human, interferon-inducible protein kinase. J. Biol. Chem. 267:1992;7871-7876.
64. Patel R. C., Sen G. C. PACT, a protein activator of the interferon-induced protein kinase, PKR. EMBO J. 17:1998;4379-4390.
65. Patel R. C., Stanton P., Mcmillan N. M. J., Williams B. R. G., Sen G. C. The interferon-inducible double-stranded RNA-activated protein kinase self-associatesin vitroin vivo. Proc. Natl. Acad. Sci. USA. 92:1995;8283-8287.
66. Patel R. C., Stanton P., Sen G. C. Role of the amino-terminal residues of the interferon-induced protein kinase in its activation by double-stranded RNA and heparin. J. Biol. Chem. 269:1994;18593-18598.
67. Patel R. C., Stanton P., Sen G. C. Specific mutations near the amino terminus of PKR differentially affect its dsRNA and dimerization properties. J. Biol. Chem. 271:1996;25657-25663.
68. Pearson R. B., Wettenhall R. E. H., Means A. R., Hartshorne D. J., Kemp B. E. Autoregulation of enzymes by pseudosubstrate prototopes: Myosin light chain kinase. Science. 241:1988;970-973.
69. Polyak S. J., Tang N., Wambach M., Barber G. N., Katze M. G. The p58 cellular inhibitor complexes with the interferon-induced dsRNA-dependent protein kinase, PKR, to regulate its autophosphorylation and activity. J. Biol. Chem. 271:1996;1702-1707.
70. Rivas C., Gil J., Melkova Z., Esteban M., Diaz-Guerra M. Vaccinia virus E3L protein is an inhibitor of the interferon-induced 2-5A synthetase enzyme. Virology. 243:1998;406-414.
71. Robertson H. D., Mathew s. M. B. The regulation of the protein kinase PKR by RNA. Biochimie (Paris). 78:1996;909-914.
72. Romano P. R., Green S. R., Barber G. N., Mathews M. B., Hinnebusch A. G. Structural requirements for dsRNA binding, dimerization and activation the human eIF-2 alpha kinase DAI inS. cerevisiae. Mol. Cel. Biol. 15:1995;365-378.
73. Romano P. R., Zhang F., Tan S.-L., Garcia-Barrio M. T., Katze M. G., Dever T. E., Hinnebusch A. G. Inhibition of the dsRNA-dependent protein kinase (PKR) by vaccinia virus E3: Role of complex formation and the E3 N-terminal domain. Mol. Cell. Biol. 1998.
74. Samuel C. E., Kuhen K. L., George C. X., Ortega L. G., Rende-Fournier R., Tanaka H. The PKR protein kinase: An interferon-inducible regulator of cell growth and differentiation. Int. J. Hematol. 65:1997;227-237.
75. Samuel C. E., Ozata K. Induction of interferons and interferon-induced genes. Biotherapy. 8:1996;183-187.
76. Schagger H., von Jagow G. Tricine-sodium dodecyl sulfate-polyacrylamide gel electrophoresis for the separation of proteins in the 1-100 kDa range. Anal. Biochem. 168:1987;368-379.
77. Schmedt C., Green S. R., Manche L., Taylor D. R., Ma Y., Mathews M. B. Functional characterization of the RNA-binding domain and motif of PKR. J. Mol. Biol. 249:1995;29-44.
78. Sharp T. V., Witzel J. E., Jagus R. A homologous region of eIF2α and vaccinia virus K3L gene product interact with the same domain in PKR. Eur. J. Biochem. 250:1997;85-92.
79. Shors T., Jacobs B. L. Complementation of deletion of the vaccinia virus E3L gene by theEscherichia coli. Virology. 227:1997;77-87.
80. Shors T., Kibler K. V., Perkins K. B., Seidler-Wulff R., Banaszak M. P., Jacobs B. L. Complementation of vaccinia virus deleted of the E3L gene by mutants of E3L. Virology. 239:1997;269-276.
81. Smith D. B., Johnson K. S. Single-step purification of polypeptides expressed inE. coli. Gene. 67:1988;31-40.
82. St. Johnson D., Brown N., Gall J. G., Jantsch M. A conserved dsRNA binding domain. Proc. Natl. Acad. Sci. USA. 89:1992;10979-10983.
83. Tanaka H., Samuel C. E. Structure of mouse PKR gene encoding the interferon-inducible RNA-dependent protein kinase. Proc. Natl. Acad. Sci. USA. 91:1994;7995-7999.
84. Taylor D. R., Lee S. B., Romano P. R., Marshak D. R., Hinnebusch A. G., Esteban M., Mathews M. B. Autophosphorylation sites participate in the activation of PKR. Mol. Cell. Biol. 16:1996;6295-6302.
85. Whitaker-Dowling P., Youngner J. S. Characteristics of a specific kinase inhibitory factor produced by vaccinia virus that inhibits interferon induced protein kinase. Virology. 37:1984;171-181.
86. Wu S., Kaufman R. J. A model for the dsRNA-dependent dimerization and activation of PKR. J. Biol. Chem. 272:1997;1291-1296.
87. Wu S. Y., Kaufman R. J. dsRNA binding and not dimerization correlates with the activation of PKR. J. Biol. Chem. 271:1996;1756-1763.
88. Yuwen H., Cox J. H., Yewdell J. W., Bennick J. R., Moss B. Nuclear localization of a dsRNA-binding protein encoded by the vaccinia virus E3L gene. Virology. 195:1993;732-744.